Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문병인 | * |
dc.contributor.author | 권기환 | * |
dc.contributor.author | 임우성 | * |
dc.contributor.author | 우주현 | * |
dc.contributor.author | 이준우 | * |
dc.contributor.author | 김현구 | * |
dc.contributor.author | 송신정 | * |
dc.date.accessioned | 2024-05-20T16:31:05Z | - |
dc.date.available | 2024-05-20T16:31:05Z | - |
dc.date.issued | 2024 | * |
dc.identifier.issn | 2297-055X | * |
dc.identifier.other | OAK-34930 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/268418 | - |
dc.description.abstract | Background: Doxorubicin is a highly effective anti-cancer drug that causes left ventricular (LV) dysfunction and induces late-onset cardiomyopathy. However, an effective and clinically applicable preventive treatment is yet to be discovered. Objective: Cardiac-Extracorporeal shockwave therapy (C-ESWT) has been suggested to treat inflammatory and ischemic diseases and protect cardiomyocytes from doxorubicin-induced cardiomyopathy. This study aims to assess the safety and efficacy of C-ESWT in the prevention of subclinical cardiotoxicity. Methods: We enrolled 64 breast cancer patients. C-ESWT group 33 patients were treated with our C-ESWT (200 shots/spot at 0.09 mJ/mm2 for 20 spots, 3 times every six weeks). The efficacy endpoints were the difference in left ventricular global longitudinal strain (LVGLS) change by 2D speckle tracking echocardiography and chemotherapy-related cardiac dysfunction (CTRCD). Echocardiography was performed on the baseline line and every 4 cycles of chemotherapy, followed by a follow-up 3,6 months after chemotherapy to compare the incidence of cardiomyopathy of subclinical LV dysfunction due to chemotherapy between the two groups. Results: Participants averaged 50 ± 9 years in age, 100% female. In the results of follow-up 6 months after the end of chemotherapy, there was a significant difference in delta LVGLS between the C-ESWT group and the control group (LVGLS; −1.1 ± 10.9% vs. −11.5 ± 11.6% p-value; <0.001). A total of 23% (15 patients) of patients developed CTRCD (Control group; 13 vs. C-ESWT group; (2). C-ESWT was performed safely without any serious adverse events. Conclusion: In this prospective study, C-ESWT established efficacy in preventing subclinical cardiotoxicity, especially in breast cancer patients using doxorubicin chemotherapy, and the safety of C-ESWT. Clinical Trial Registration: ClinicalTrials.gov, identifier (NCT05584163). 2024 Song, Woo, Kim, Lee, Lim, Moon and Kwon. | * |
dc.language | English | * |
dc.publisher | Frontiers Media SA | * |
dc.subject | breast cancer | * |
dc.subject | cancer therapy-related cardiac dysfunction | * |
dc.subject | cardiac extracorporeal shock wave therapy | * |
dc.subject | doxorubicin | * |
dc.subject | left ventricular global longitudinal strain/LV GLS | * |
dc.title | A prospective randomized controlled trial to determine the safety and efficacy of extracorporeal shock waves therapy for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin | * |
dc.type | Article | * |
dc.relation.volume | 11 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | Frontiers in Cardiovascular Medicine | * |
dc.identifier.doi | 10.3389/fcvm.2024.1324203 | * |
dc.identifier.wosid | WOS:001170833700001 | * |
dc.identifier.scopusid | 2-s2.0-85185695621 | * |
dc.author.google | Song | * |
dc.author.google | Shinjeong | * |
dc.author.google | Woo | * |
dc.author.google | Joohyun | * |
dc.author.google | Kim | * |
dc.author.google | HyunGoo | * |
dc.author.google | Lee | * |
dc.author.google | Jun Woo | * |
dc.author.google | Lim | * |
dc.author.google | Woosung | * |
dc.author.google | Moon | * |
dc.author.google | Byung-In | * |
dc.author.google | Kwon | * |
dc.author.google | Kihwan | * |
dc.contributor.scopusid | 문병인(7101878644;56119062300) | * |
dc.contributor.scopusid | 권기환(57203037966) | * |
dc.contributor.scopusid | 임우성(27167744500) | * |
dc.contributor.scopusid | 우주현(56241303800) | * |
dc.contributor.scopusid | 이준우(55789929300;57209289345) | * |
dc.contributor.scopusid | 김현구(57205888468;57261045500;57246947100) | * |
dc.date.modifydate | 20240607115458 | * |